Antitumor Assessment: Publications

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N. (2012) “Relief of profound feedback inhibition of mitogenic signaling by Raf inhibitors attenuates their activities in BRAFV600E melanomas.” Cancer Cell 22: 668-82.

Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura J, Manova-Todorova K, Moore M, Antonescu CR, Besmer P. (2012) “Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.” Proc. Natl. Acad. Sci.USA 109: E2276-83.

Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK. (2012) “The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.” Clin Cancer Res 18: 2638-47

Clegg NJ, Wongvipat J, Tran C, Ouk S, Dilhas A, Joseph J, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones PM, Klang M, Smith ND, de Stanchina E, Wu N, Ouerfelli O, Rix P, Heyman R, Jung ME, Sawyers CL, Hager, JH. (2012) “ARN-509: a novel anti-androgen for prostate cancer treatment.” Cancer Res 72: 1494-503

Zammarchi F, de Stanchina E, Supakorndej T, Martires K, Riedel E, Corben A, Bromberg J, Cartegni L. (2011) “Anti-tumorigenic potential of STAT3 alternative splicing modulation.” Proc. Natl. Acad. Sci.USA 108: 17779-84.

Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, de Stanchina E, Longo V, Herz E, Iyer S, Wolchok J, Larson SM, Wiesner U, Bradbury MS. (2011) “Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.” J Clin Invest 121: 2768-80.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. (2010) “Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.” Blood 115: 2919-2927.

Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. (2009) “Genetic dissection of the MiR17 approximately 92 cluster of microRNAs in Myc-induced B-cell lymphomas.” Genes Dev 23: 2806-11.

Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. (2009) “Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.” J. Clin. Invest 119: 3000-3010.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulik K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. (2009) “Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.” Proc. Natl. Acad. Sci.USA 106: 8368-8673.

Real PJ, Tosello V, Palomero V, Castillo M, Hernando-Monge E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon Cardo C, Ai W, Ferrando A. (2009) “Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL.” Nature Med 15: 50-58.